SNCB, known for its role in Alzheimer’s disease, was decreased in GBM tissue 4-fold compared to peritumoural-control tissue and inhibits phospholipase D2 (PLD2) [47] which is oncogenic [48]. This evidence concerns the gene PLD2 and glioblastoma.